GET DAILY SIGNALSSNDL vs TLRY: Retail Focus Meets Diversified Growth in Cannabis
Key Takeaways
- Both SNDL and TLRY are diversified Canadian cannabis operators, but SNDL leans on retail (cannabis and liquor) while Tilray Brands spans beverages, wellness, pharmaceutical distribution, and international medical cannabis.
- SNDL recently delivered record free cash flow (FCF, or cash left after operating and capital spending) and returned to positive adjusted operating income, even as a non-cash impairment widened its reported net loss.
- Tilray Brands posted record quarterly revenue led by its beverage segment and international expansion, but it still records net losses and negative adjusted free cash flow.
- Tickeron AI Verdict: SNDL — based on more consistent cash generation, a debt-free balance sheet, and disciplined capital returns.
- For deeper context, explore SNDL Major News, SNDL Today's Price Move, TLRY Major News, and TLRY Today's Price Move.
- To see how AI-driven strategies approach names like these, explore the curated Trending AI Robots.
Setting the Context
This stock comparison examines two of the most widely followed names in the cannabis sector: SNDL Inc. (SNDL) and Tilray Brands, Inc. (TLRY). Although both are Canadian-headquartered operators with roots in regulated cannabis, they have evolved into very different businesses, making their relative performance a useful lens for traders and investors weighing diversification against focus. This comparison is relevant for those tracking the cannabis and consumer-staples space, as well as for anyone evaluating market positioning, cash generation, and growth catalysts across two volatile, low-priced equities.
SNDL Overview and Recent Results
SNDL Inc. operates as a diversified Canadian retailer and producer. It is Canada's largest private-sector liquor retailer, running 165 locations under banners such as Wine and Beyond, Liquor Depot, and Ace Liquor, alongside a 193-store cannabis retail network (Value Buds and Spiritleaf). The company also operates cannabis cultivation and wholesale through its Cannabis Operations segment and holds a sizable U.S. medical-cannabis exposure via its investment in the multistate operator Parallel. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In recent weeks, SNDL reported third-quarter results that highlighted a mixed operating picture. Revenue declined modestly, while a non-cash goodwill impairment in Cannabis Operations pushed the headline operating line into a loss. Beneath that, however, the company delivered record quarterly free cash flow and returned to positive adjusted operating income, supported by record gross margins in both retail segments. Management announced a strategic review of Cannabis Operations, exited the unprofitable domestic dried-flower category, and reduced its Kelowna facility workforce. The company also repurchased shares and is exploring a substantial issuer bid (SIB, a formal offer to buy back shares from shareholders).
TLRY Overview and Recent Results
Tilray Brands, Inc. has evolved into a multi-segment consumer platform spanning cannabis, craft beverages, wellness products, and pharmaceutical distribution. Its distribution arm, largely anchored by Germany's CC Pharma, and its beverage portfolio—expanded recently through the acquisition of the BrewDog craft-beer business—now account for a substantial share of revenue, reducing reliance on the Canadian cannabis market. The company also operates a growing international medical-cannabis footprint, with strength in Germany, the United Kingdom, Poland, and Italy.
In recent market activity, TLRY reported record quarterly revenue, up roughly 23% year over year, driven by an 82% increase in beverage revenue and strong international growth. Gross margin improved, and the company reaffirmed its forward adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance. At the same time, Tilray still records net losses and negative adjusted free cash flow, and its shares have declined sharply over the year-to-date period. Recent federal marijuana reclassification news lifted the broader cannabis sector, adding volatility to the name.
Head-to-Head Comparison
The two companies differ most clearly in their business models and growth drivers. SNDL is a retail-heavy, Canada-focused operator whose liquor and cannabis store networks generate steady cash flow, while its Cannabis Operations segment remains a turnaround story. TLRY is a broader consumer platform whose growth increasingly comes from beverages, pharmaceutical distribution, and international medical cannabis rather than domestic flower sales.
On momentum, Tilray has delivered stronger top-line growth and clearer international catalysts, including the BrewDog acquisition and a brewing partnership with Carlsberg. SNDL, by contrast, offers stronger cash-generation consistency, a debt-free balance sheet, and active capital returns. Risk profiles also diverge: SNDL carries execution risk in Cannabis Operations and U.S. regulatory uncertainty around Parallel, while Tilray faces persistent cannabis price compression, beverage-legacy headwinds, and negative adjusted free cash flow despite its revenue scale.
In terms of market sentiment, both stocks have been volatile and are down meaningfully year to date. Tilray tends to react more sharply to U.S. regulatory headlines, while SNDL's moves have been more closely tied to its own cash-flow and restructuring progress. From what I see, this distinction matters for positioning in the sector.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and relative positioning, Tickeron's AI would currently favor SNDL over TLRY. The assessment leans on SNDL's record free cash flow, its return to positive adjusted operating income, a debt-free balance sheet, and disciplined shareholder capital returns, which together suggest a more stable and self-sustaining financial profile. Tilray offers arguably stronger growth optionality and regulatory catalysts, but its persistent net losses and negative adjusted free cash flow imply less consistency in trend. This conclusion is probabilistic rather than definitive and reflects current observable conditions rather than a forecast of future returns.
Using AI Tools for Market Context
I often turn to Tickeron’s AI Trading Bots when evaluating how systematic strategies handle names like these in volatile sectors. The platform offers a range of bots with transparent performance records, odds-of-success estimates, and detailed trade histories that span multiple years. This helps provide an additional data-driven layer to the fundamental comparison without replacing individual judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TLRY turns positive, indicating new upward trend
TLRY saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 63 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, 39 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (7.254). P/E Ratio (-2.679) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement